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Prostate cancer is the most commonly diagnosed malignancy among men, but few 
genetic factors that drive prostate cancer initiation have been identified.  The WD repeat 
domain 77 (Wdr77) protein is essential for cellular proliferation when it localizes in the 
cytoplasm of epithelial cells at the early stage of prostate development.  In the adult 
prostate, it is transported into the nucleus and functions as a co-regulator of the androgen 
receptor to promote cellular differentiation and prostate function.  This developmental 
process is reversed during prostate tumorigenesis i.e., Wdr77 is translocated from the 
nucleus into the cytoplasm to drive proliferation of prostate cancer cells.  In this study, 
we used in vivo genetic studies to investigate the role of Wdr77 in prostate tumorigenesis.  
We found that prostate-specific deletion of Wdr77 abolished prostate tumor initiation 
induced by loss of the tumor suppressor Pten.   Mechanistically, Wdr77 ablation inhibited 
E2F3 activation and enhanced TGFbeta signaling, leading to attenuated cellular 
proliferation induced by loss of Pten.  These findings establish an essential role of Wdr77 
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Prostate cancer is the most commonly diagnosed malignancy and the second 
leading cause of cancer-related death among men in the United States.1, 2  Prostate cancer 
develops through multiple clinical stages, including prostatic intraepithelial neoplasia 
(PIN), adenocarcinoma and metastasis.2  A few genes that initiate prostate cancer or/and 
promote prostate cancer progression have been identified, including the tumor suppressor 
Pten, the gene rearrangement TMPRSS2-ERG, and c-Myc.3, 4   Some genes (such as Sox9, 
Hoxb13 and Nkx3.1) and pathways (such as WNT signaling) involved in prostate 
development are found reactivated in cancer initiation and progression.5 However, there 
is still a need to determine additional drivers of prostate cancer that could help to 
understand prostate tumorigenesis and become the targets of new therapies.      
The WD repeat domain 77 (Wdr77) protein is composed of 342 amino acid 
residues and 7 putative WD-40 repeats and was identified as a component (MEP50) of 
the methylosome complex6, a subunit (WD45) of the SMN complex7, and a novel 
androgen receptor-interacting protein (p44).8, 9  Wdr77 localizes in the cytoplasm of 
epithelial cells and is required for cell proliferation at the growth stage of prostate 
development.9-11  In contrast, in the adult prostate, Wdr77 expression is decreased and the 




cofactor to establish and maintain luminal epithelia in a growth-arrested, fully 
differentiated state (G1/G0 phase). Thus, Wdr77 provides for the integrated regulation of 
proliferation and differentiation of prostate epithelial cells through its distinct subcellular 
localization during prostate development.   
The increased Wdr77 gene expression and Wdr77 protein translocation from the 
nucleus to the cytoplasm is associated with age-related prostatic intraepithelial 
hyperplasia and prostate tumorigenesis.9-11 The cytoplasmic Wdr77 is also required for 
the proliferation of prostate cancer cells and growth of prostate tumor xenografts.9, 11, 12  
Therefore, the molecular event involving Wdr77 in prostate development is reversed 
during cancer tumorigenesis.   Further studies indicated that Wdr77 is required for cell 
proliferation via modulating cell cycle progression and expression of some cell growth 
regulators. 12,13  More recently, we found that Wdr77 expression also causes non-
sensitivity of proliferating cells to TGFβ signaling, thereby contributing to cellular 
proliferation during tumorigenesis.14   
The tumor suppressor gene, Pten, encodes a lipid phosphatase that catalyzes the 
dephosphorylation of phosphatidylinositol-trisphosphate, resulting in down-regulation of 
PI3K-AKT signaling pathway.15  AKT, when activated, modulates a variety of 
downstream effectors involved in cell proliferation, apoptosis, cell growth, and 
metabolism.16  Deletion or mutation of the Pten gene is one of the most frequent genetic 
alterations in many human cancers, including prostate cancer.17  Loss of the Pten gene in 
prostate epithelial cells in the mouse results in the development of PIN and prostate 




Based on the results of our previous studies, we hypothesize that Wdr77 is 
required for the initiation of tumorigenesis driven by the loss of Pten. To investigate this, 
we have set the following two aims:  
Aim 1:  Determine if Wdr77 is essential for initiation of Pten deficient prostate 
tumorigenesis.  








2.1 Prostate Cancer 
Prostate adenocarcinoma is the second leading cause of cancer in American men, 
following closely behind skin cancer. In terms of mortality, prostate cancer ranks third, 
following lung and colorectal cancer.21 However, unlike these other cancers, data 
suggests that the incidence of prostate cancer can be clearly defined as a function of 
age.22, 23 The induction of cancer can normally be attributed to a multitude of extraneous 
factors, such as smoking leading to lung cancer or alcohol abuse leading to colorectal 
cancer.24, 25 However, the induction of prostate cancer can be spontaneous, not 
necessarily needing exogenous influence for prostatic dysplasia.26  
According to the data generated by the Surveillance, Epidemiology, and End 
Reports Program (SEER), it is estimated that 161,360 men will be newly diagnosed with 
prostate cancer in 2017.27 Unfortunately, it is also estimated that 26,730 men will 
succumb to the disease in the same year. Nonetheless, there have been significant 
reductions in the incidence and mortality rates since 2005, with an average decrease in 
prostate cancer incidence by 4.8% per year for the last ten years,  as seen in Figure 1.27 In 
part, this may be due to an overall increase in the amount of people with access to 
healthcare. In addition, advances in technology have also contributed to a decline in the 
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incidence and mortality of prostate cancer through educational programs and early 
detection, respectively.28 
 
Figure 1.  Incidence of prostate cancer as reported by SEER.27 
 
Prostate cancer is initially a hormone dependent neoplasm, reliant upon androgen 
binding to and inducing transactivation of the Androgen Receptor (AR) which causes the 
transcription of genes responsible for proliferation, survival, and metastasis.29 This causes 
a rapid proliferation of epithelia, progressing in stages that range from low grade 
dysplasia, to highly malignant and distant metastases.29, 30 Nearly all cases of prostate 
cancer are of luminal origin, with a very few percentage of cases being of basal origin 




2.1.1 Prostate Cancer Detection and Diagnosis 
Considering prostate cancer’s strong correlation with age, it is recommended that 
men undergo screening at age 40.33  Although there is variability about the concise age at 
which the screening should occur, data suggests that 40 years old is approximately the 
time when the prostate will begin the process of regrowth, leading to either mild 
dysplasia or perhaps the initiating stages of prostate adenocarcinoma. Current practical 
methods for screening include administration of the digital rectal examination (DRE) and 
testing the blood serum levels of the Prostate Specific Antigen (PSA).34, 35 The theory 
behind the DRE is simple, a physician will insert a finger into the rectum and feel along 
the prostate to detect whether there is an enlargement or presentation of any nodules.36 
Any abnormality that is detected will be biopsied and referred to a pathologist. The PSA 
test relies upon measuring the blood serum levels of PSA. PSA levels above 4.0 ng/ml 
suggest an abnormal prostate, which would then require a biopsy and referral to a 
pathologist.37  
Despite routine screening, there are many documented cases where the DRE and 
PSA have exhibited both false positives and false negatives.38-40 For instance, the DRE is 
a purely qualitative method whereby the results may depend on the physician’s technique 
and relative discretion.41 The PSA test is also subject to scrutiny because the basal level 
of PSA in blood serum can be affected in a multitude of ways.42 For example, PSA levels 
may be higher than the suggested baseline due to factors such as age, race, and use of 
medication.43 For these reasons, it is imperative to develop novel techniques and identify 
new biomarkers for early detection of prostate cancer.35, 44, 45  
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Upon a positive diagnosis of a neoplasm by a pathologist, the sample is then 
staged by the Gleason grading system. In this system two numbers are assigned to a 
sample based upon the morphology of the two most representative regions in the 
sample.46 If the area of focus looks like well differentiated prostate epithelium, a value of 
1 is assigned to the region. A value of 5 is assigned to nondifferentiated neoplasia, where 
it likely exists as a solid mass of cells where polarity, structural organization and cell type 
are generally indistinguishable.47, 48 Values assigned between 1 and 5 represent a 
progressive and more malignant phenotype, in succession (Figure 2). Typically, multiple 
biopsy cores are used to gather a more comprehensive understanding of the stage of the 
cancer so the appropriate treatment options can be determined.49  




2.1.2 Prostate Cancer Treatment 
Current treatment options for localized prostate cancer include radical 
prostatectomy, brachytherapy and radiation therapy. The type of treatment a patient 
receives is largely dependent upon the stage of the disease upon diagnosis, but is also 
limited by factors including age, relative health and many other factors.51 Nonetheless, 
radical prostatectomy has been the main treatment option since the early 1990s.52 
However, brachytherapy and radiation therapy have also begun to be widely used, often 
in combination for the best results irrespective of potential side effects.51  
 Patients with localized/organ confined prostate cancer are the best candidates for 
a radical prostatectomy to have a considerable success margin and low rate of 
recurrence.53 The reason for this is that this procedure involves removal of the entire 
prostate. If the cancer was improperly staged, it is possible that cancer cells may 
repopulate in a distant, undiagnosed metastasis. Despite the relative success of radical 
prostatectomy, a strong association between incontinence and erectile dysfunction 
complicates the decision to opt for this generally successful procedure.54, 55  
Brachytherapy is an internal radiation therapy, as the delivery of is accomplished by 
insertion of dozens of radioactive seeds into the prostate.56 These seeds deliver high 
dosages of radiation to the prostate, nearly exclusively, to kill cancerous cells.57, 58 
Traditional radiation therapy, also known as electronic beam radiation therapy (EBRT), is 
an external radiation therapy which targets the prostate using a laser.59 Treatment time is 
significantly longer, and there are far more side effects because the application of 
radiation is nonspecific.60, 61 
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Treatment of prostate cancer does not always take a linear approach, however. 
Recurrence of the disease, especially in late stages, complicates the decision on which 
treatment to use. As there are now many drugs on the market and in preclinical phases 
that are approved for treatment of late stage prostate cancer, the decision as to which 
molecules to target has become more difficult.62, 63 It is now widely accepted that prostate 
cancer is a heterogeneous disease, consisting of multiple phenotypes and there are many 
implications in this discovery.64,65 For instance, targeting a specific molecule may inhibit 
the proliferation of a subset of prostate cancer cells, but may select for a subset of cancer 
cells to proliferate in a therapy-induced manner.62  
As an example, androgen deprivation therapy is performed to stop the growth of 
the prostate. However, in nearly all cases, the neoplasm recurs and presents as the lethal 
hormone refractory phenotype. Cells that were responsive to ADT are killed, but cells 
that are androgen insensitive persist (Figure 3). Conventional medicines and therapies fail 
to work at this point and the 5-year survival rate for men with metastatic prostate cancer, 
post-ADT is abysmal, at approximately 30%.27 For these reasons, it is imperative to gain 
insight into the mechanisms of prostate tumorigenesis such that we may develop 




Figure 3. Androgen deprivation therapies.66 
 
2.2 Mouse Models of Prostate Cancer  
Development of the prostate involves a complex series of events and cooperation 
between multiple signaling pathways, with each regulating the various stages of prostatic 
growth and maturation. Because of the difficulty in studying human prostate 
development, a multitude of models have been established that closely resemble the 
stages of human prostate development.67, 68 Since spontaneous prostate cancer induction 
remains an uncommon phenomenon, many different mouse strains have been genetically 
manipulated to harbor mutations that mimic the transformation of the prostate as it 
progresses from a normal phenotype to the most malignant, metastatic prostate 
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adenocarcinoma.69, 70 There are multiple ways to accomplish this, however determination 
of whether the benefits outweigh the limitations may be specific to each individual 
study.71 
Technological advancements have made it possible to study cancer in diverse 
ways.72, 73 While in vitro research is indisputably valuable, data that is generated through 
cell culture often does not recapitulate the disease as it would behave in vivo.74 However, 
utilization of mouse models has opened the door for translational research. Allografts, 
Xenografts, Patient derived Xenografts (PDX) and Genetically Engineered Mouse 
Models (GEM) currently stand at the forefront of the translational research.75  
2.2.1 Xenograft and GEM Models 
Allografts, xenografts and PDX are very similar in nature. Each procedure 
transplants cells or tissues to a mouse to generate a tumor (Figure 4).76 However, 
allografts are generated by cells or tissues derived from a mouse that is of identical 
genetic makeup.77 Xenografts differ slightly, and the transplanted cells are from that of an 
established human prostate cancer cell line, such as the common LNCaP or DU145.78 
PDX may soon be the gold standard as it holds the most promise to recapitulate human 
disease because the transplanted cells or tissues comes directly from a patient and retains 
molecular features unique to the primary tumor.79 Implementation of the PDX has the 
potential to revolutionize prostate cancer treatment by identifying which treatments may 





Figure 4. Generation of xenograft mouse model.81 
GEM typically serve as “knockout” models to study the role of a particular gene 
on development or pathogenesis of a disease.26 A common tactic for gene deletion is to 
generate a mouse that harbors an inducible transgene, whereby the gene is deleted upon 
crossbreeding using a mouse harboring the Cre recombinase or in response to chemical 
treatment like Tamoxifen.82 To generate a Cre knockout mouse, loxP sites will be 
inserted on opposite ends of the desired construct, which consist of a strong mammalian 
promoter, like CMV, and will be followed by the gene of interest, a reporter, such as 
GFP, and an enhancer.83 This synthetic construct will then be injected into a mouse ES 
cells, screened for homologous recombination and thereafter into brown mice blastocysts 
to create a chimera.84 These mice are then crossbred with mice harboring the Cre 
recombinase to generate a knockout mouse (Figure 5).83 Knockout mice such as the tp53 
mouse, cMYC mouse and Pten-/- mouse have contributed significantly to the 





Figure 5. Generation of Cre knockout mice. 85 
2.2.2 The Pten Null Mouse Model 
Recapitulation of the progression of human prostate cancer can be observed in the 
Pten deficient GEM. Pten is a critical negative regulator for the PI3K/AKT pathway, and 
yields constitutive activation of proliferative and anti-apoptotic effectors.86  Upon 
prostate specific deletion of Pten, mice begin to present with prostate intraepithelial 
neoplasia (PIN) in approximately 6 weeks and invasive adenocarcinoma in as little as 9 
weeks (Figure 6).18 The majority of tumors that develop in mice are of luminal origin, 
however, deletion of Pten results in intraductal neoplasia, with cells expressing both K8 
and K5.87  Upon castration, most of these intermediate and normal luminal cells are 
apoptosed. Similar to human disease, restoration of androgens causes regeneration of the 
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prostate, and regeneration of the tumor mass which is now insensitive to androgen 
deprivation.88  
 
Figure 6. Prostate cancer progression as a result of Pten loss.18 
 
2.3 The Mouse Prostate  
The mouse shares homology with the human prostate, and though its function is 
conserved, the architecture is starkly different (Figure 7, A versus B). For instance, 
human prostates are a solid gland whereas the mouse prostate is defined by 4 unique 
zones, named because of their spatial orientation. Human prostates are grossly defined 
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into the central, peripheral and transition zones. On the other hand, mouse prostates are 
divided into the dorsal, lateral, ventral and anterior lobes, with each lobe bearing unique 
characteristics.89 Although their gross appearances may suggest they may bear distinctive 
characteristics, at the microscopic level, the human and mouse prostate are more alike 
than different. Nonetheless, they both produce seminal fluid to nourish and protect sperm 
in addition to regulating musculature for continence. For the purposes of this study, we 
will focus on the mouse prostate.  
The mouse prostate consists of ductal acini, extending and branching distally in a 
periurethral manner. The mouse prostate has three cellular layers: the luminal epithelia, 
basal epithelia, and a stromal compartment.89 The stroma has been implicated in 
paracrine signaling to enrich prostatic proliferation in an AR dependent manner.90 The 
luminal epithelia are secretory cells, expressing CK8 and CK18, responsible for prostate 
secreted proteins such as PSA. Luminal epithelia are responsible for induction of the 
majority of prostate adenocarcinomas. Basal cells express CK5 and CK15, and are mostly 
responsible for maintaining a protective barrier for the lumen.91 Interestingly, it has been 
shown recently that basal cells can be transformed into cancer cells, a phenomenon once 
thought to be improbable.92, 93 Within the epithelial population, there exists a small subset 
of neuroendocrine cells. The precise function of neuroendocrine cells is unknown, 




Figure 7. Morphology of the prostate gland. 96 A. Adult human prostate. B. Adult mouse prostate.  
 
2.4 Hormonal and Molecular Regulation of the Prostate Development  
2.4.1 The Androgen Receptor 
The Androgen Receptor (AR) is a 110 kilo Dalton protein, consisting of a 
transactivation domain (NTD), a DNA-binding domain (DBD), a hinge region and a 
ligand-binding domain (LBD).97 The AR is classified as a steroid hormone receptor, 
found in the accessory sex organs of both males and females. In the male, expression of 
the AR in the testes, mammary glands, and prostate is responsible for maintenance of 
differentiated secretory epithelia (Figure 8). However, the AR can also exhibit 
proliferative characteristics during both development and induction of tumorigenesis.98 
Interestingly, the dual functionality of the AR is dependent upon ligand, as well as 










2.4.1.1 Androgen Receptor in Prostate Development 
The Androgen Receptor (AR) is a member of the nuclear receptor superfamily 
that shuttles from the cytoplasm to the nucleus and acts as a transcription factor. Upon 
binding ligand, 5-alpha-dihydroxytestosterone (DHT) or testosterone (T), AR 
disassociates from a complex with Hsp56/70/90 and homodimerizes, whereby it is then 
shuttled into the nucleus and binds to the Androgen Response Element (ARE) to promote 
the expression of a subset androgen targeted genes such as PSA, TMPRSS2, NKX3.1 and 
KLK2 (Figure 9).101, 102 In the mature murine prostate, the AR is expressed in both the 
epithelium and stroma, but is not generally expressed in basal cells. However, it is also 
postulated that intermediate cells and a small subset of basal cells do express the AR, and 
have the potential to transdifferentiate into a luminal cell given the appropriate selective 
pressures.103 Additionally, research has revealed that the development of the prostate is 
driven by paracrine AR signaling. Specifically, it was reported that mesenchymal AR 
drives the proliferation of the epithelial cord which becomes the prostatic duct.104   
The urogenital mesenchyme (UGM) has been suggested to regulate prostatic 
development through a multitude of modalities such as through promotion of epithelial 
bud formation and branching morphogenesis.105 Given the role of UGM in prostate 
development and the expression of the AR initially only in embryonic mesenchyme, it 
can be confirmed that mesenchymal AR regulates the induction of UGE proliferation and 
canalization.106, 107 This suggestion is corroborated by the observation that androgen 
targeted genes, specifically a large and diverse array of growth factors such as EGF and 
FGF, have been shown to promote cellular proliferation in vivo as well as in vitro.108, 109 
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However, the modulation of cellular signaling is not a singular event leading to prostate 
development, but expression of these growth signals by transactivation of AR is 










2.4.1.2 The Androgen Receptor in Prostate Cancer 
Prostate cancer is initially dependent upon androgens, and administration of 
androgen ablation therapy leads to an initial inhibition of AR transactivation and yields 
positive results such as tumor regression. However, this is overcome after a median 
period ranging between 18-24 months, presenting as a highly proliferative, highly 
metastatic and lethal hormone refractory prostate cancer (HRPC).111, 112 Although there 
have been many advances into what is known about HRPC, little is known about the role 
of androgen and the AR in the initiation of prostate tumorigenesis. In this stage, the 
cancer cells will rely on intratumoral androgen synthesis, non-genomic signaling and the 
selective pressures in the prostatic microenvironment will select for these androgen 
insensitive cells (Figure 10).113, 114 
Figure 10. Alternative androgen receptor signaling.115 
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It has been reported that the AR is necessary for the initiation of prostate 
tumorigenesis.29 However, there is little direct evidence to substantiate these claims. For 
instance, it has been reported that loss of AR in Pb-Cre Mice bearing an AR deletion 
present PIN, but do not progress to prostate adenocarcinoma.116 However, mice harboring 
gain of function AR mutations have been shown to mimic human disease and lead to 
prostate adenocarcinoma, followed by metastases to distant organs.117 It has been 
reported that 159 mutations of the AR can be found in prostate cancer cases (Figure 
11).118 Thus far, a few factors that contribute to development of HRPC have been 
identified. Sensitizing AR to ligand or AR amplification, intracrine androgen synthesis, 
AR being transactivated by alternative ligands, and AR being activated by other effector 
molecules, i.e.  AKT, are all examples of how modifications in the AR signaling pathway 
contribute to HRPC.119, 120 
Figure 11. Mutations of the androgen receptor.121 
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2.4.2 The PI3K/PTEN Pathway  
2.4.2.1 PI3K 
The phosphatidylinositol (3,4,5)- phosphate kinase (PI3K) pathway represents a 
key element in regulating the proliferative capacity of a cell, and is often observed to be 
constitutively active in prostate cancer.122 PI3K’s main function is to catalyze the 
phosphorylation of phosphatidylinositol 4,5-biphosphate (PIP2) to phosphatidylinositol 
3,4,5-triphosphate (PIP3). This promotes recruitment of AKT to the membrane, where it 
is then phosphorylated by PDK1 and phosphorylated on T308. AKT is further 
phosphorylated on S473 by mTORC2, whereby it can then go on and phosphorylate a 
variety of proteins, including AR to promote nuclear translocation, as well as 
mTORC1.123 
 The serine/threonine kinase mTORC1 is a major target of AKT and has been 
shown to be essential for translation by activation of S6K and 4EBP1.123  In a conditional 
knockout model, loss of mTORC2 has been shown to inhibit the induction of prostate 
tumorigenesis.124 AKT also inhibits antiproliferative effectors by phosphorylation as 
well, such as the proapoptotic and growth inhibitory proteins BAD, FOXO1 and 
GSK3β.125 However, PI3K also exerts beneficial effects, as it has been shown to be 
essential for branching morphogenesis in prostate development in cooperation with 
mTOR.126 Through gain of function mutations and/or loss of inhibitory molecules, PI3K 
exerts its proliferative capacity and drives a cell towards rapid, ungoverned growth 




Figure 12. The PI3K/AKT signaling pathway.128 
 
2.4.2.2 PTEN  
The phosphatase and tensin homolog deleted on chromosome 10 (PTEN) is a 
protein lipid phosphatase, whose responsibility lies largely in the removal of a phosphate 
group from phosphatidylinositol (3,4,5)-trisphosphate/PtdIns(3,4,5)P3 (PIP3), converting 
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it to phosphatidylinositol 4, 5-phosphate/PtdIns(4,5)P2 (PIP2,) thereby stopping the PI3K 
signaling.129, 130 Loss of the tumor suppressor, PTEN, is evident in up to 70% of all 
incidences of prostate cancer. Loss of PTEN occurs by either deletion on chromosome 
10, chromosomal inversions or translocations, or mutation (Figure 13).131, 132   
 
Figure 13. Mutations of the Pten gene.86 
Although cancer is a multistep process, it has been shown that loss of PTEN 
results in the induction of cellular growth leading to hyperplasia, as seen in the mouse 
model.133 Loss of PTEN function has been shown to be sufficient to induce growth, 
however, loss of PTEN alone is not sufficient for progression of tumorigenesis in 
humans. As the key negative regulator of PI3K, loss of function results in accumulation 
of AKT, which can then activate a plethora of downstream targets (Figure 14).133 
Experiments with transgenic mice showed that loss of Pten results in rapid tumor growth 
and metastases. On the other hand, restoring PTEN function results in a drastic inhibition 







Figure 14. Regulation of PI3K/AKT axis by PTEN.136 
 
PTEN had originally been thought to be an exclusively cytoplasmic protein, 
regulating PI3K activity. However, it has been determined that PTEN has additional 
functions and traverses the nuclear membrane to serve as a tumor suppressor and acts as a 
key facilitator in prostate development.137-139 In addition, it has been shown that Pten is 
essential for differentiation of luminal epithelia and also for embryological development, 
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as Pten deficient mice die in utero.140  Although loss of Pten is typically observed later in 
the progression of prostate tumorigenesis, Pten loss is often coupled to loss of another 
gene, as a bigenic model, to study the effects of a protein in the development of prostate 
cancer.141 Generally speaking, GEM are used to study loss-of-function (LOF) mutations, 
however, gene knock-in models do exist. However, the capacity to which knock-in 
models are representative of the molecular mechanisms of human disease is still unclear.  
2.5 The Wdr77 Protein  
Wdr77, also known as p44, is a 44 kDa protein that consists of 342 amino acids 
whose sequence is identical to that of methylosome 50, a subunit in the methylosome 
complex.6, 142 Wdr77 is a member of the WD repeat domain family, which consists of a 
diverse set of proteins with numerous functions. However, the common theme of WD 
repeat proteins is the formation of a beta propeller structure that serves as a scaffold to 
facilitate protein-protein interaction.143  Wdr77 is unlike any of the traditional WD repeat 
proteins as it has an unstructured N terminal domain, which has yet to be resolved by 
crystallography. Wdr77 has been shown to facilitate the symmetric di-methylation of 
adjacent arginine residues by Protein Arginine Methyltransferase 5 (PRMT5) by initially 
binding the target protein and thereafter orienting PRMT5 to perform methyltransferase 
activities.144 It has been observed that WDR77 serves as a cofactor for the Androgen 
Receptor (AR), driving transcription of proteins involved in the maturation and 




2.5.1 Wdr77 in Prostate Development 
Wdr77 was initially identified as a cofactor for the Androgen receptor in the 
mouse prostate by coimmunoprecipitation detected by silver staining. Upon purification, 
it was evident that Wdr77 was identical in sequence to Mep50, a member of the 
methylosome and a subunit to the SMN assembly unit.  However, Wdr77 elicited unique 
properties in the prostate. It was first observed that Wdr77 formed a stable complex with 
the Androgen Receptor, driving a subset of androgen targeted genes.8 Real time PCR 
analysis revealed that the downstream AR expressed genes served as regulators for 
differentiation and proliferation.  In the initial phase of prostatic development (<28 days), 
Wdr77 localizes in the cytoplasm in a complex with PRMT5 in the methylosome 
complex. Interestingly, the proliferative function of Wdr77 is AR-independent. More 
recent studies have shown that targeted deletion of Wdr77 during mouse prostatic 
development resulted in immature prostatic ducts and ablation of the prostate secreted 
proteins.146  
Using a genetically engineered mouse model, researchers were able to establish a 
prostate specific Wdr77 floxed mouse whereby infection with Adenovirus harboring the 
Cre recombinase would effectively delete Wdr77. Upon deletion, it was observed that the 
maturation of the prostate was retarded, evident by molecular and histopathological 
analyses (Figure 15). These mice exhibited a dramatic decrease in the infoldings within 
the lumen in addition to flattened luminal epithelia and a stark decrease in prostate 
secreted proteins. Western blot and RT-PCR analyses revealed a significant induction of 
p27/Cip1a, which alongside cell cycle analyses, demonstrate that loss of Wdr77 induced 
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G1 cell cycle arrest.9, 146 p27/Cip1a, which alongside cell cycle analyses, demonstrate that 
loss of Wdr77 induced G1 cell cycle arrest.  
 Figure 15. Wdr77 deletion results in immature prostatic ducts.146 
Further investigations have shown that the expression and localization of Wdr77 
correlates with prostatic development. In wild-type mice, immunohistochemical staining 
was performed to determine the relative expression and localization pattern of Wdr77. It 
was observed that in the growth stage, when the prostate is rapidly proliferating, Wdr77 
expression was high in the cytoplasm of the luminal epithelia.9 However, beginning at 28 
days, Wdr77 began to undergo a translocation event which shuttled it to the nucleus. 
Interestingly, this subcellular shuttling coincided with the differentiation of the luminal 
epithelia. At 45-60 days, Wdr77 is nearly exclusively localized to the nucleus whereby it 
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serves as a cofactor for the androgen receptor.147 These data suggested that Wdr77 has 
dual roles in the development of the prostate and that the Wdr77 translocation event may 
mediate the switch between the proliferating and differentiating prostate (Figure 16).148 
Figure 16. Nucleocytoplasmic shuttling of Wdr77 during prostate development.147 
It was later demonstrated that Wdr77 is essential for both proliferation and 
differentiation of mouse prostate epithelial cells. Fusion of Wdr77 with a nuclear 
localization signal (NLS) revealed a large induction in the expression of differentiation 
marker cytokeratin 18.149 This forced nuclear localization also resulted in a significant 
reduction in cell proliferation in mouse prostate epithelial cells. However, fusion of 
Wdr77 to a nuclear exclusion signal (NES) drastically enhanced the proliferative index in 
mouse prostate epithelial cells (MPECs). In addition, NLS or NES fused Wdr77 was 
stably transfected into MPECs expressing the Large T-temperature sensitive SV 40 
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antigen (SV40 LTts). Cultured in the permissive temperature of 33C, the temperature by 
which the SV40 is activated and the cells proliferate, NES-Wdr77 exhibited high rates of 
cellular proliferation. These results were similar to the cells lines expressing wildtype 
Wdr77 or those transfected with the empty vector. In cells expressing NLS-Wdr77, the 
proliferation rate was significantly decreased, like the cells infected with Wdr77 
shRNA.149 
Cultured in the non-permissive temperature of 37C, the temperature by which the 
SV40 is inactivated and the cells do not proliferate, NES-Wdr77 again exhibited high 
rates of cellular proliferation, as opposed to all other treatments. However, NLS-Wdr77 
exhibited high expression of cytokeratin 18 in addition to significant induction of the 
androgen receptor signaling as reported by measuring androgen reporter element activity 
in a dual luciferase reporter assay. Taken together, these data demonstrate that 
cytoplasmic Wdr77 is both sufficient and essential to drive cellular proliferation. 
Additionally, these data show that nuclear Wdr77 is essential for epithelial 
differentiation.149 
2.5.2 Wdr77 in Prostate Cancer 
Hosohata first observed a marked increase in the expression of WDR77 protein 
and mRNA levels in prostate cancer cells.145 Similar to prostate cancer, data suggests a 
similar upregulation of WDR77 in hyperplastic regions in a multitude of cancers.150, 151 It 
was demonstrated that in prostate cancer, WDR77 undergoes a subcellular shuttling event 
from the nucleus to the cytoplasm (Figure 17). The effect of this translocation event has 
proved to be not only essential, but sufficient to initiate cellular growth, as shown by 
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fusion of WDR77 to a nuclear exclusion signal. Gao and Wang reported that fusion of 
WDR77 to a nuclear localization signal exhibited strong inhibitory effects on cellular 
growth as well as tumor xenografts and exhibited a marked increase in the expression of 
the differentiation marker, K18. Deletion of WDR77 in prostate cancer cells and tumor 
xenografts abolished cellular growth.147 Given the essential nature of this protein for the 
progression of tumorigenesis, elucidation of its role in the initiation of tumorigenesis has 
not been determined.  
 Figure 17. Wdr77 undergoes a translocation to the cytoplasm in PIN.9 Normal luminal epithelia retain 
nuclear Wdr77, indicated by the solid black arrows (a-d). Wdr77 is localized to the cytoplasm in neoplastic 
regions, as indicated by the arrowheads.  
 
More recent investigations have described the role of Wdr77 in several cancer 
models. For instance, it has been shown that Wdr77 is essential for growth of prostate 
cancer cells and tumor xenografts.148 Similar to the previous studies demonstrating the 
necessity of cytoplasmic Wdr77 in prostate epithelial cells, LNCaP cells were stably 
transfected with NES-Wdr77, NLS-Wdr77, wildtype Wr77, or empty vector of Wdr777 
shRNA. NES-Wdr77, wildtype Wdr77 and the empty vector control elicited high rates of 
cellular growth and proliferation. However, NLS-Wdr77 and Wdr77 shRNA transfected 
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cells abolished cellular growth and proliferation significantly by induction of G1 cell 
cycle arrest (Figure 18).149 
Figure 18. Wdr77 has dual functionality dependent upon localization.12 A. NES-p44 forces Wdr77 into 
cytoplasm and results in the rapid growth of mouse epithelial cells. B. NLS-p44 forces Wdr77 into nucleus 
and induces differentiation, as shown by K18 staining.  
 
Wdr77 also exerts an essential role in various cancers.152 Consistent with prostate 
cancer, the function of Wdr77 is dependent upon subcellular localization in lung cancer. 
However, in lung cancer cells, nuclear Wdr77 is essential for cellular proliferation. 
Normally, Wdr77 is not expressed in the mature lung.14 It has yet to be reported why this 
phenomenon occurs, however, it may be due to variation with regulation and utilization 
of different molecular and hormonal pathways. Nonetheless, it is imperative to determine 
the role that Wdr77 extends in the initiation of prostate cancer. Our current model for the 
function of Wdr77 is shown in Figure 19. In the normal growing luminal epithelia, 
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and promotes differentiation. However, after some external signal or period of time, 
Wdr77 is trafficked to the nucleus whereby it initiates the regrowth of the prostate, 
resulting in hyperplastic lesions. 
 





MATERIALS AND METHODS 
 
3.1 Prostate-Specific Deletion of Pten and Wdr77 Genes in the Mouse 
PtenloxP/loxP mice (C;129S4-Ptentm1Hwu; Stock Number 006440) were purchased 
from Jackson Laboratory and Wdr77loxP/loxP mice were generated as previously described 
by us.153  The PtenloxP/loxP mouse was crossed with the Wdr77loxP/loxP mouse to generate 
PtenloxP/loxP;Wdr77loxP/loxP  mouse.  PtenloxP/loxP or PtenloxP/loxP;Wdr77loxP/loxP mouse was 
then crossed with PRR2Bi-Cre mouse  to generate mice that were prostate-specific 
deletion of Pten gene (PtenloxP/loxP;Cre or Ptenpc-/-) or both Pten and Wdr77 genes 
(PtenloxP/loxP;Wdr77loxP/loxP ;Cre or Ptenpc-/-;Wdr77pc-/-).154  For gene typing, the genomic 
DNA was isolated from tail or prostate gland of mouse at the age of 21 day old and 
subjected to PCR analysis with primers as described.18, 153 Mice were handled in 
accordance with the guidelines published in the National Institutes of Health Guide for 
the Care and Use of Laboratory Animals.  The Morehouse College School of Medicine’s 
Institutional Animal Care and Use Committee approved all the experimental procedures 








3.2 Antibodies  
Antibodies against and Pten (D4.3), Ki-67 (D3B5), Akt (pan C67E7), p-AKT 
(Ser473), and p-S6 ribosomal protein (Ser235/236) were obtained from Cell Signaling 
Technology.  Antibodies against AR (N-20), E2F3 (N-20), and pSMAD3 (Ser208) were 
obtained from Santa Cruz Biotechnology. The BrdU antibody was obtained from BD 
Biosciences. The antigen purified anti-Wdr77 antibody was described previously 153.  
 
3.3 Immunohistochemistry 
The prostate gland was dissected from WT, Ptenpc-/- or Ptenpc-/-;Wdr77pc-/- mouse 
at the age of 21, 60, or 120 days and fixed with 10% formalin overnight at 4o C.   The 
fixed prostate gland was embedded in paraffin and sectioned (5µm).  Prostate sections 
were subjected to washes in xylene, dehydration in graded ethanol (70%-100%), and then 
washed in phosphate buffered saline (PBS).  Following dehydration, the sections were 
subjected to the citrate antigen retrieval followed by a 12-minute treatment with 3% H202 
in PBS for endogenous peroxidase blocking.  To reduce nonspecific binding of the 
primary antibody, the sections were blocked with 4% fish gelatin for 30 min.  The 
prostate sections were incubated with the primary antibody overnight at 4°C and then 
with a secondary peroxidase-labeled antibody (Biocare Medical) for 30 min, washed with 
PBS and incubated with 4+ Streptavidin-HRP (Biocare Medical) for 30 min.  The 
sections were then washed with PBS and the signal was visualized by application of 3,3'-




3.5 Cell Culture and Cell Growth Assay 
Mouse prostate epithelial cells were isolated from prostate glands of PtenloxP/loxP 
and  PtenloxP/loxP;Wdr77loxP/loxP mice as described previously by us 149 and cultured in 
Keratinocyte Serum Free Medium (KSFM) (Gibco) supplemented with 2% Fetal Bovine 
Serum plus 1% Pen-Strep, epidermal growth factor (0.1 ng/mL), and bovine pituitary 
extract (23 µg/mL).  The Pten gene or both Pten and Wdr77 genes were deleted by 
infection of epithelial cells with Ad5-CMV-Cre-GFP (15 particles per cell; Vector 
Development Laboratory, Baylor College of Medicine) as described. 149 The control cells 
were infected with Ad5-CMV-GFP at the same time with the same viral particles per cell.  
Cells were harvested at 7 days post adenovirus infection for analysis.   For cell growth 
assay, cells (5x 105 cells per well) were plated in a 24 well culture plate in triplicate and 
counted every day for four days.   For BrdU incorporation assay, cells were plated in a 
chamber slide (8-well, 1.0x104 cells/per well) and grown overnight.  BrdU was added to 
the medium at the final concentration of 10 µM.   Cells were incubated for 2 hrs. and 
immunostained with anti-BrdU antibody (BD Biosciences) according to a previously 
published protocol. 149  
 
3.6 Western Blot Analysis 
Whole cell lysates were obtained using the Passive Lysis Buffer (Promega) 
supplemented with Protease and Phosphatase inhibitors (Fischer Scientific).  Protein 
concentration was determined using the Bradford Assay (Bio-Rad) with BSA as the 
standard.  Following SDS-PAGE, protein was transferred to a nitrocellulose membrane 
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(NC) at 6V overnight.  NC membrane was blocked for 30 minutes in 3% milk in TBST 
(Tris buffered saline with 0.05% Tween-20).  Thereafter, the membranes were incubated 
in primary antibody in 2% BSA-TBST, for 2 hours.  NC membranes were then washed 
3x with TBST in five-minute intervals, followed by incubation in secondary antibody 
labeled with horseradish peroxidase (HRP) in 2% BSA-TBST, for 1.5 hours.  NC 
membranes were then washed 4x5 min with TBST.  Protein was then detected using an 
enhanced chemiluminescent substrate (Western Lightning-Plus ECL, Perkin Elmer). 
 
3.7 Cell Cycle Analysis 
Cells were trypsinized, washed with PBS and fixed with cold ethanol (70%) for 
overnight at 4 oC.   Cells were pelleted by centrifugation at 2,000 rpm for 5 min and 
washed with PBS.  Cells were stained with propidium iodide (PI) and submitted to cell 
cycle analysis on the Accuri C6 Flow Cytometer (BD Biosciences).   Data were analyzed 
using FloJo software (FloJo).  
 
3.8 Real-Time PCR 
Total RNA was isolated from cells using the TRIzol reagent (Thermofisher).   
cDNA was generated using the Superscript III First-Strand Synthesis System 
(Thermofisher).  Real-time PCR was performed with Go-Taq qPCR master mix 





3.9 Statistical Analysis 
Data are presented as the means of three or more independent experiments ± the 
standard deviation.  A 2-tailed unpaired student t-test was used to determine whether 
differences between control and experiment samples were statistically significant.  P 






4.1 Generation of Mice Bearing Prostate-Specific Deletion of Pten and Wdr77 Genes 
Previous studies have demonstrated that Wdr77 was essential for growth of 
normal prostate epithelial cells as well as prostate cancer cells and prostate tumor 
xenografts.9, 11  However, it has yet to be shown the role of Wdr77 in prostate 
tumorigenesis in vivo.  To explore this, we used the Pten gene knockout mouse model, 
which closely mimics human prostate cancer.11, 147  To generate mice that were 
homozygous mutants for Pten (Ptenpc-/-) and both Pten and Wdr77 genes (Ptenpc-/-
;Wdr77pc-/-) in the prostate, we crossed PtenloxP/loxP and PtenloxP/loxP;Wdr77loxP/loxP mice 
with PRR2Bi-Cre mice, respectively.   The prostate-specific deletion of Pten and Wdr77 
genes were confirmed by genomic typing (Figure 20, lane 6). 
Figure 20.  The prostate-specific deletion of Pten and Wdr77 genes in the mouse. Gene typing of genomic 
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Consistent with previously published reports, Pten protein expression in the 
cytoplasm of the prostate luminal epithelia with sporadic nuclear staining (Figure 21 
panel A) and Wdr77 protein expression in the nucleus (panel C) were observed.12, 18  The 
majority of prostate epithelial cells of Ptenpc-/-;Wdr77pc-/- mice lost both Pten and Wdr77 
protein expression (Figure 21, panels B and D), with a few cells (about 1-3%) still 
expressing Pten or Wdr77 but at low levels (inserts, indicated by black arrows).   
Figure 21. Immunostaining of Pten and Wdr77 proteins in prostate glands of WT and 
PtenloxP/loxP;WdrloxP/loxP;Cre mice. 
 
As expected, loss of the Pten gene led to up-regulation of the phosphorylated 




Ptenpc-/-;Wdr77pc-/- mice relative to the WT mouse (Figure 22a, panels B-E versus panel 
A; (Figure 22, lanes 2 and 4 versus lanes 1 and 3), indicating that Wdr77 gene deletion 
did not affect AKT activation induced by Pten loss.   Loss of the Wdr77 gene did not 
affect expression of the Pten gene or reverse versa (Figure 22b, lanes 2 and 4 versus lanes 
1 and 3), suggesting no physiological regulation between Pten and Wdr77. 
 
Figure 22.  Immunostaining and western blot analysis of pAKT.  (a)  AKT phosphorylation 
induced by Pten gene deletion.  Immunostaining of phosphorylated AKT (pAKT) in prostate 
tissues derived from WT, Ptenpc-/-, and Ptenpc-/-;Wdr77pc-/- mice.  (b)  Western blot analysis of 
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4.2 Cytoplasmic Wdr77 is Essential for Prostate Tumor Initiation Induced by Pten 
Loss 
Prostate glands were derived from Ptenpc-/- and Ptenpc-/-;Wdr77pc-/- mice at the ages 
of 1, 2 and 4 months (Table 1) and submitted to the analyses.  Examined following 
Hematoxylin and Eosin (H&E) staining and consistent with previous observations, Pten-
null mice exhibited PIN lesions (PIN, circled) and tumors (T, circled) at the age of 2 
months (Figure 23).18, 155   Interestingly, examination of Ptenpc-/-;Wdr77pc-/- mouse 
prostate revealed a few PIN lesions (PIN, circled) and small tumors (T, circled) (Figure 
24).  The tumor incidence of Pten-null was increased as mice aged (Figure 25).  The 
incidence of PIN and tumors in Ptenpc-/-;Wdr77pc-/- mice was drastically decreased in 
mice at the ages of both 2 and 4 months (Figure 25).  
 
Table 1. Ages, Genomic Types and Number of Mice Analyzed 
 Genomic Type 
Age (months) PtenloxP/loxP Pten pc-/- Ptenlox/PloxP;Wdr77loxP/loxP 
Ptenpc-/-;Wdr77pc-/- 
 
1 2 5 2 5 
2 2 5 2 5 





Figure 23. Loss of Pten induced prostate tumorigenesis and formation of PIN.  The prostate tissue was 
derived from the Ptenpc-/- mouse at the age of 2 months and stained with H&E.  Tumor (T) regions are 





Figure 24. Loss of Wdr77 inhibited prostate tumorigenesis induced by Pten gene deletion.  The prostate 
tissue was derived from the Ptenpc-/-;Wdr77pc-/- mouse at the age of 2 months and stained with H&E.  Tumor 





Figure 25. The incidence of PIN (a) and prostate tumor (b) in Ptenpc-/- and Ptenpc-/-;Wdr77pc-/- mice.  
Prostate glands were derived from mice at the ages of 2 (n=5) and 4 (n=7) months and PIN and tumor 
lesions were quantified for each prostate.  Tumor or PIN incidence = numbers of glands with tumor or PIN 
per 100 glands.   Data are presented as the means of 5 (at the age of 2 m) or 7 (at the age of 4 m) prostates. 
 
Immunostaining of the prostate derived from Ptenpc-/-;Wdr77pc-/- mouse with anti-
Wdr77 antibody revealed that cells in PIN and tumor regions still expressed Wdr77 
(Figure 26).  In contrast, Wdr77 was absent in the benign epithelial cells (Figure 26, 
circled by red lines).  These results suggest that PIN and tumors were derived from cells 
in which Wdr77 was not deleted.  Thus, Wdr77 expression is essential for prostate PIN 




Figure 26. Cytoplasmic Wdr77 is essential for prostate initiation induced by Pten gene deletion.   
Immunostaining of Wdr77 (brown) in the prostate tissue derived from the Ptenpc-/-;Wdr77pc-/- mouse at the 
age of 2 months.  Benign regions are circled by red lines (top panel).   Red arrows indicate benign epithelial 
cells expressing Wdr77 in the nucleus.   
 
We have previously reported that at the early stage of prostate development, 
Wdr77 is localized in the cytoplasm to drive cellular proliferation.147  In contrast, it is 
transported into the nucleus in adult prostate to drive cellular differentiation.  During 
prostate tumorigenesis, this developmental process is reversed, i.e., Wdr77 is transported 
from the nucleus into the cytoplasm to initiate cellular proliferation. 147  We investigated 
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whether a similar event happens during prostate tumorigenesis driven by the Pten 
deletion.  Similar to that observed during prostate tumorigenesis, Wdr77 is localized in 
the nucleus of normal prostate epithelial cells (Figure 27, top panels) and in contrast, 
Wdr77 is transported into the cytoplasm in hyperplasia (middle panels) and tumor 
(bottom panels) lesions.11  Cells in which Wdr77 was not deleted but localized to the 
nucleus were also observed in normal luminal epithelia (Figure 26, indicated by red 
arrows).  We previously demonstrated that WDR77 in the cytoplasm is essential and 
sufficient to drive cellular proliferation and, in contrast, when localized in the nucleus, it 
inhibited cell growth and promoted cellular differentiation.149   Thus, WDR77 
cytoplasmic translocation may be also required for prostate tumorigenesis driven by Pten 
gene deletion.  
 
Figure 27. Wdr77 cytoplasm translocation is associated with prostate tumorigenesis induced by Pten gene 
deletion.   The prostate tissue was derived from the Ptenpc-/- mouse at the age of 2 months and 




4.3 Loss of Wdr77 Inhibited Cellular Proliferation Induced by the Pten Deletion via 
E2F Transcriptional Factor  
We previously demonstrated that cytoplasmic Wdr77 is essential for proliferation 
of prostate epithelial cells as well as prostate cancer cells.11, 147  Quantification of 
proliferation was accomplished by Ki-67 immunostaining (brown, indicated by black 
arrows) on WT, Ptenpc-/-, and Ptenpc-/-;Wdr77pc-/- prostate sections (Figure 28a).  In WT 
prostate, about 4% of epithelial cells were Ki-67-positive (Figure 28b).  However, the 
deletion of the Pten gene significantly enhanced the proliferation rate of epithelial cells in 
PIN (5.5-fold) and tumor (7.7-fold) regions (Figure 28b, middle and right panels) but no 
effect on the proliferation of benign prostate epithelial cells (left panel).  Simultaneous 
deletion of both Pten and Wdr77 genes resulted in the proliferation rate of benign prostate 




Figure 28. Loss of Wdr77 inhibited cellular proliferation induced by Pten gene deletion.   (a)  The prostate 
tissue were derived from the WT, Ptenpc-/-, and Ptenpc-/-;Wdr77pc-/- mice at the age of 2 months and stained 
for Ki-67 (brown).  (b) The percentage of Ki-67 positive cells in WT (n=2), Ptenpc-/- (n=5), and Ptenpc-/-
;Wdr77pc-/- (n=7) prostate.   
 
However, the proliferation rate of epithelial cells in PIN and tumor regions of Ptenpc-/-
;Wdr77pc-/- prostate  is indistinguishable with that observed in the Ptenpc-/- prostate, 
consistent with the fact that Wdr77 was not deleted in these lesions (Figure 26).  
Prostate epithelial cells were isolated from PtenloxP/loxP and 
PtenloxP/loxP;Wdr77loxP/loxP mice  and infected with adenovirus harboring the Cre 
recombinase to delete Pten (Figure 29a, lane 2) and Pten plus Wdr77 genes (lanes 4 and 
6).   Of note, the efficiency of Ad-mediated gene deletion is between 95-100% .156  Pten 
deletion led to AKT phosphorylation Figure 29, lane 2b versus lane 1) and enhanced 
growth of prostate epithelial cells (Figure 30, left), consistent with previous reports.18, 157  
However, deletion of both Pten and Wdr77 genes also led to AKT phosphorylation 
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(Figure 29b, lane 4 versus lane 3) but inhibited growth of prostate epithelial cells (Figure 
30, right). 
 
Figure 29. Gene deletion of Pten or/and Wdr77 led to activation of PI3K/AKT axis. (a) Gene typing of 
prostate epithelial cells derived from the PtenloxP/loxP and PtenloxP/loxP;Wdr77loxP/loxP mice and infected with 
adenovirus harboring GFP (Ptenf/f , lanes 1, 3, 5) or Cre recombinase (Pten-/-, lanes 2, 4, 6). (b)  Loss of 
Wdr77 did not affect Pten-AKT-mTOR, Pten-AKT-BAD and Pten-AKT-GSK3β signaling pathways.   
Western blot analysis of indicated proteins isolated from Ptenf/f, Pten-/-, Ptenf/f;Wdr77f/f; and Pten-/-
;Wdr77-/- epithelial cells.  
 
To assess proliferation, we used a BrdU incorporation assay.  As reported, the 
percentage of BrdU-positive Pten-null epithelial cells was significantly higher than that 
of control epithelial cells (Figure 30).157  On the converse, Pten- and Wdr77-null cells 
exhibited a significant decrease in cell proliferation relative to that of control cells 
(Figure 30).  Thus, Wdr77 mediates cellular proliferation induced by the Pten gene 
deletion.  The isolated epithelial cells lost AR expression (Figure 31, lanes 2 and 3), 
suggesting that the regulation of cell growth by Pten and Wdr77 is AR-independent. 
a b 
 
 1 2 3 4 
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Figure 30. Loss of Wdr77 inhibited cellular proliferation induced by Pten gene deletion in mouse prostate 
epithelial cells. The growth curves of prostate epithelial cells derived from the PtenloxP/loxP (left), and 
PtenloxP/loxP;Wdr77loxP/loxP (right) mice and infected with adenovirus harboring GFP (left: Ptenf/f; Right: 
Ptenf/f;Wdr77f/f) or Cre recombinase (Left: Pten-/- and Right: Pten-/-;Wdr77-/-).  
Figure 31. Loss of Wdr77 inhibited cellular proliferation induced by Pten gene deletion in mouse prostate 
epithelial cells in an AR-independent manner. (a) Percentage of BrdU-positive epithelial cells infected with 
adenovirus harboring GFP or Cre recombinase.  Cell were grown in the presence of BrdU for 2 hr. and 
submitted for immunostaining for BrdU.  (b)  Western blot of whole cell lysates made from LNCaP, Ptenf/f , 
and Ptenf/f;Wdr77f/f cells with anti-AR antibody and anti-actin antibodies. 
 
Pten loss promotes phosphorylation of AKT, which in turn phosphorylates 
multiple targets resulting in an increase in cell proliferation, cell survival, metabolism and 
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protein synthesis.16  We next investigated which signaling pathway(s) activated by Pten 
loss was affected by Wdr77 gene deletion.   As reported, Pten loss resulted in 
phosphorylation of AKT, S6 ribosomal protein (rpS6) and GSK3β (Figure 29) but loss of 
Wdr77 did not affect these phosphorylation events (lane 4), indicating that loss of Wdr77 
had no effect on Pten-AKT-GSK3β (metabolism) and Pten-AKT-mTOR-S6K (protein 
synthesis) signaling pathways induced by Pten loss.157  Loss of Pten gene or Pten and 
Wdr77 genes did not induce cell apoptosis (Figure 32).  We also observed that loss of 
Wdr77 gene did not inhibit phosphorylation of the BAD protein induced by Pten deletion 
(data not shown).  So, Wdr77 gene deletion also did not affect cell survival induced by 
Pten loss.   
 
Figure 32. Loss of Wdr77 did not affect apoptosis in Ptenf/f, Pten-/-, Ptenf/f;Wdr77f/f; and Pten-/-;Wdr77-/- 















It was reported previously that Pten loss enhanced cellular proliferation by 
activating the pRB-E2F pathway.158, 159  The pRB-E2F pathway plays a critical role in 
regulating cellular proliferation because it regulates expression of many genes that are 
required for cell cycle progression.160  To determine whether Wdr77 exerts influence on 
this process, we performed immunostaining of E2F3, a member of the E2F family of 
transcription factors.161  As shown in Figure 33, WT mice presented very low expression 
of E2F3 (panel A).  However, Pten deletion resulted in strong nuclear expression of E2F3 
(panel B) , consistent with previous reports.159  Interestingly, upon simultaneous deletion 
of Wdr77 and Pten genes, E2F3 expression in the benign region resembled that of the WT 
mouse with little to no expression (Figure 33, panel C).  Of note, high levels of E2F3 are 
observed in the tumor region   (Figure 33, panel C, circled by red line), where Wdr77 is 
not deleted (Figure 16).  This finding indicates that Wdr77 is required for expression of 
E2F3 induced by Pten deletion.   
 
Figure 33. Loss of Wdr77 blocked E2F3 expression induced by Pten gene deletion.  The prostate tissues 
were derived from the WT, Ptenpc-/-, and Ptenpc-/-;Wdr77pc-/- mice at the age of 2 months and immunostained 
for E2F3 and  phosphorylated Rb (pRb).   
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 Rb interacts with E2F proteins to block its function in the activation of S-phase 
genes.160 The phosphorylation of Rb abolishes its interaction with E2F proteins, thereby 
relieving its inhibitory effect on cell-cycle progression.  In WT mice, Rb phosphorylation 
was minimal (Figure 33, panel D), as opposed to the strong pRb signal exhibited in the 
Pten-null mouse prostate (panel D).  This result indicates that Pten loss leads to Rb 
phosphorylation to relieve its inhibitory effect on E2F transcriptional factors.  In the 
double knockout mutant, pRb presented in epithelial cells of both normal (Wdr77-null) 
and tumor (circled by red lines, Wdr77-positive) regions (panel F).   Thus, loss of Wdr77 
did not affect Rb phosphorylation induced by Pten deletion.  
 
4.4 TGFβ Signaling is Activated in Ptenpc-/-;Wdr77pc-/- Mice 
The anti-proliferative effects of TGF-β signaling are lost during tumorigenesis, 
leading to hyper cellular proliferation.162-164  More recently, we found that Smad2/3 
phosphorylation, TGFβ-mediated transcription, and TGFβ2 and TGFβ receptor type II 
(TGFβRII) expression were dramatically induced when Wdr77 expression was silenced.14  
We further demonstrated that Wdr77 expression caused the non-sensitivity of 
proliferating cells to TGFβ signaling, thereby contributing to cellular proliferation during 
lung tumorigenesis.14 We analyzed the TCGA prostate cancer data set 
(https://cancergenome.nih.gov/).  Gene set enrichment analysis (GSEA) indicates that 
genes regulated by TGFβ were over-represented on the gene list, whose expression is 
altered in prostate cancer (Figure 34a).  The gene heatmap reports show the altered 
55 
 
expression of TGFβ target genes in majority of prostate cancer patients (Figure 33b).  
Thus, the TGFβ signaling is lost in prostate cancer.    
 
Figure 34. Loss of TGFβ signaling associated with prostate cancer.  (a)  GSEA enrichment plot indicates 
that genes regulated by TGFβ were over-represented on the gene list, whose expression is altered in 




We also analyzed the DNA microarray data set (GSE25140) generated from the 
mouse with the prostate-specific Pten deletion.165  GSEA indicates that genes regulated 
by TGFβ were over-represented on the gene list, whose expression is altered in Pten 
knockout prostate (Figure 35a).  The gene heatmap reports changes of TGFβ target genes 
in Pten knockout prostate versus WT prostate (Figure 35b).  Among these genes, 23 
genes (up-regulated by TGFβ in WT prostate) are down regulated and 5 genes (repressed 
by TGFβ in WT prostate) are up regulated in the Pten-null prostate.  This analysis 
suggests that the TGFβ signaling is down-regulated in the Pten gene knockout prostate.  
We performed immunostaining of SMAD3 in WT, Ptenpc-/-, and Ptenpc-/-;Wdr77pc-/- 
prostate sections  and detected nuclear SMAD3 staining in normal prostate epithelial cells 
(Figure 35c, Examples are indicated by black arrows.), indicating that the TGFβ signaling 
is active.  SMAD3 protein was diffuse into the cytoplasm in hyperplasia and tumor cells 




   
Figure 35.  Loss of Wdr77 prevented inactivation of the TGFβ signaling.   (a)  GSEA enrichment plot 
indicates that genes regulated by TGFβ were over-represented on the gene list, whose expression is 
regulated by Pten loss.  (b)  Genes targeted by TGFβ are visualized by heatmap.  The red and blue colors 
represent higher than average and lower than average expression of particular genes in the Pten-null 
prostate, respectively.  (c)  Immunostaining of phosphorylated SMAD3 (pSMAD3) in prostate tissues 
derived from WT, Ptenpc-/-, and Ptenpc-/-;Wdr77pc-/- mice at the age of 2 months.   (d)  diagram of the Pten-




Consistent with this observation, Pten loss led to significant down regulation of 
TGFβ2, TGFBRII and TGFBRIII expression in prostate epithelial cells (Figure 36).  Loss 
of Wdr77 reactivated the TGFβ signaling (p-SMAD3 expression) inactivated by Pten loss 
in vivo (Figure 35c, panel D, circled) and restored TGFβ2 and TGFBRIII expression in 
Pten-null epithelial cells (Figure 36).  Our findings suggest that Wdr77 may also play an 
important role to block the anti-proliferative effects of the TGFβ signaling during prostate 
tumorigenesis. 
 
Figure 36. RT-PCR analysis of expression of genes involved in TGFβ signaling. RNAs were isolated from 
Ptenf/f, Pten-/-, Ptenf/f;Wdr77f/f; and Pten-/-;Wdr77-/- epithelial cells and submitted for real-time PCR 
analysis.  Fold-change = relative expression in loxP-floxed cells/ relative expression in cells with deletion 






4.5 AR Signaling is Not Affected in Ptenpc-/-;Wdr77pc-/- Mice  
It was reported that the loss of the Pten gene resulted in up-regulation of AR 
expression.166  We observed the same result in Ptenpc-/- and Ptenpc-/-;Wdr77pc-/- mice 
(Figure 37, panels B-D versus panel A).  Although AR protein levels were slightly 
increased, the androgen signaling (reflected by expression of androgen hallmark genes) 
was down-regulated in the Pten-null mouse prostate (Figure 3).   We previously reported 
that Wdr77 loss selectively affected expression of a set of AR-target genes in the mouse 
prostate and in prostate cancer cells.9,153  We previously observed that Wdr77 regulates 
cellular proliferation is independent on the AR signaling.12, 148, 167  We obtained the same 
result that Wdr77 regulated proliferation of mouse epithelial cells in which AR protein is 
not expressed.  How the AR signaling altered by Pten loss or/and Wdr77 subcellular 
transportation may contribute to prostate tumorigenesis requires additional studies.  
 
Figure 37: AR expression is induced by Pten loss.  Immunostaining of AR in prostate tissues derived from 







Figure 38. Pten loss decreased the AR signaling in the prostate.   (a)  GSEA enrichment plot indicates that 
genes regulated by AR were over-represented on the gene list, whose expression is altered by Pten loss.  (b)  






Wdr77 regulates proliferation and differentiation of prostate epithelial cells during 
the development through its subcellular localization.  This developmental process is re-
activated during prostate tumorigenesis.  The data from this study indicate that Wdr77 
expression as well as its cytoplasmic localization is required for prostate tumor initiation 
induced by Pten loss.     
Pten is frequently altered in cancers, suggesting it plays a fundamental role in 
many malignancies.  Pten loss promotes phosphorylation of AKT, which in turn 
phosphorylates multiple targets resulting in an increase in cell proliferation, cell survival 
and protein synthesis (Figure 29b).  An important question is which signaling activated 
by Pten loss plays an essential role in prostate tumorigenesis.  Sox4 expression was up-
regulated as a result of activation of Pten-AKT-mTOR signaling induced by Pten loss 
and loss of the Sox4 gene attenuated invasive phenotype of prostate tumors.168  β-Catenin, 
a downstream target of Pten-AKT-GSK3β signaling, is essential for many developmental 
processes and has been implicated in tumorigenesis in many tissues, including prostate 
cancer.169, 170  It has been shown that β-catenin is required for prostate development and 
its over-expression can promotes invasive prostate cancer in the Pten deletion model.171  
These findings suggest that the activation of Pten-AKT-mTOR or/and
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Pten-AKT-GSK3B signaling is critical for prostate cancer progression driven by Pten 
loss.  
 
5.1 Wdr77 is Essential for Tumorigenesis Induced by Pten Loss 
Pten loss resulted in phosphorylation of AKT, S6 ribosomal protein (rpS6), 
GSK3β and BAD proteins, indicating the activation of Pten-AKT-mTOR, Pten-AKT-
BAD and Pten-AKT-GSK3β signaling pathways.   But, deletion of Wdr77 gene did not 
affect the activation of these pathways and induce cell apoptosis, suggesting that Wdr77 
did not affect Pten-AKT-mTOR, Pten-AKT-BAD and Pten-AKT-GSK3B signaling 
pathways.  However, we found that Pten loss induced E2F3 expression and Rb 
phosphorylation in prostate epithelial cells.   As the consequence, cellular proliferation 
was significantly enhanced.  Deletion of Wdr77 abolished prostate tumor initiation 
induced by Pten loss, correlated with decreased E2F3 expression but not Rb 
phosphorylation.    This finding suggests that Pten-AKT-E2F signaling axis may be 
required for prostate tumor initiation induced by Pten loss.   
We observed that Pten loss significantly enhanced BrdU-positive (proliferative) 
epithelial cell populations and induced E2F3 expression and Rb inactivation 
(phosphorylation), consistent with the fact that Pten gene loss induces cellular 
proliferation. 17, 155, 157  Loss of Wdr77 significantly reduced cellular proliferation induced 
by Pten loss.  These results are consistent with our previous observations that Wdr77 
plays an essential role in proliferation of prostate epithelial and cancer cells.147,149  Wdr77 
deletion reduced E2F3 expression induced by Pten loss, suggesting that Wdr77 is 
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necessary for the maintenance of E2F3 protein levels, which is required for cell cycle 
progression from G1 to S phase.  The mechanism of how Wdr77 regulates E2F3 
expression is currently under investigation.  Wdr77 also targets several growth factors as 
well as growth inhibitors.13  Whether expression of these factors by Wdr77 contributes to 
prostate tumorigenesis induced by Pten loss in vivo is also under investigation.             
 
5.2 Loss of Wdr77 Restores TGF-β Signaling 
Most normal adult cells are fully differentiated and generally quiescent.  TGFβ 
acts as a key physiological factor that ensures the maintenance of cell quiescence.172, 173  
Tumorigenesis is involved in the loss of cellular sensitivity to TGFβ signaling. 174   Our 
analysis of the TCGA prostate cancer dataset across 498 prostate cancer patients and 52 
normal prostate tissues supports this conclusion.  Down-regulation of the TGFβ signaling 
was observed in prostate cancer patients when compared to the normal prostate tissues.  
Similarly, the TGFβ signaling is also down-regulated in the Pten knockout prostate.  In 
this study, we observed inactivation of the TGFβ signaling (loss of p-SMAD3 
immunostaining) in prostate epithelial cells following loss of Pten, which was blocked by 
loss of Wdr77.  In the previous study, we described that Wdr77 abrogated TGFβ growth 
suppression in proliferating cells.14  
These results suggest that Wdr77 cytoplasmic translocation induced by loss of 
Pten is not only required for cellular proliferation but may also play an important role to 
block the anti-proliferative effects of the TGFβ signaling, which is essential for prostate 
tumorigenesis. This study suggests that Wdr77 expression and its cytoplasmic 
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translocation are required for cellular proliferation by maintaining E2F3 expression and 






Although there have been large strides made studying prostate cancer, the primary 
objective has been to identify molecules and signaling pathways necessary for the 
progression of prostate cancer. However, little is known about which molecules and 
signaling pathways are essential for the initiation of prostate cancer. Thus far, it has been 
described in previous publications that the developmental pathways are often “switched 
back on” in the initiating stages of prostate cancer, but there is uncertainty as to how this 
is accomplished.96  
In this study, we have developed a bigenic mouse model in which prostate-
specific deletions of both Wdr77 and Pten genes are generated in the epithelium using 
Cre-loxP site-specific recombination.  We report here that deletion of Wdr77 abolished 
PIN and prostate tumor development initiated by homozygous loss of Pten, 
demonstrating the essential role of Wdr77 in prostate tumor initiation.  We further show 
that Wdr77 is necessary for maintenance of cellular proliferation induced by the loss of 
Pten through modulation of the E2F transcription factor.  In addition, we demonstrated 
that Wdr77 is critical for suppressing TGFβ signaling in vivo, suggesting that Wdr77 




Taken together, these results suggest that Wdr77 is a critical mediator in the 
initiation of prostate cancer.  These data support investigations into methods of 
pharmacological silencing of Wdr77 or inhibiting the ability of Wdr77 to traverse the 
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